About CalciMedica
CalciMedica (NASDAQ:CALC) focuses on developing critical care therapies for patients with acute and life-threatening inflammatory diseases. This biopharmaceutical company is especially concentrated on leveraging its expertise in calcium release-activated calcium (CRAC) channel inhibitors to treat conditions such as acute pancreatitis and other diseases where CRAC channels play a key role. CalciMedica aims to revolutionize the way acute inflammatory conditions are treated by advancing its leading compound through clinical trials and ultimately to the market, making a significant impact on patient care. The company, solely listed on NASDAQ, embodies a mission to address the unmet medical needs in critical care with innovative, effective treatments.
Snapshot
Operations
Products and/or services of CalciMedica
- Auxora, a CRAC channel inhibitor for treating acute pancreatitis and COVID-19 pneumonia.
- Development of novel CRAC channel inhibitors for autoimmune diseases and neuroinflammatory disorders.
- Research on CRAC channel modulation to address acute lung injury.
- Exploration of therapies for critical care conditions, including sepsis and acute kidney injury.
- Investigation into applications of CRAC channel inhibitors for cardiac ischemia-reperfusion injury.
- Study of potential treatments for inflammatory bowel disease leveraging CRAC channel inhibition.
CalciMedica executive team
- Dr. A. Rachel Leheny Ph.D.CEO & Director
- Mr. Eric W. RobertsChief Business Officer & Vice Chairman of the Board
- Dr. Sudarshan Hebbar M.D.Chief Medical Officer
- Mr. Michael J. Dunn B.A., M.B.A.President & COO
- Dr. Anjana Rao Ph.D.Co-Founder and Scientific Advisor
- Dr. Patrick Hogan Ph.D.Co-Founder and Scientific Advisor
- Dr. Stefan Feske M.D.Co-Founder and Scientific Advisor
- Dr. Kenneth A. Stauderman Ph.D.Co-Founder & Chief Scientific Officer
- Mr. Stephen B. BardinChief Financial Officer
- Mr. John M. Dunn J.D.General Counsel